Consolidation treatment (With ICIs)

Phase 3

Consolidation treatment (With ICIs) is one of 29 therapeutic programs targeting Colorectal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Colorectal CarcinomaRecruiting

Colorectal CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

30 competitors in Colorectal Carcinoma

#DrugCompanyPhaseTrials

Stivarga

Verzenio

Tukysa

Avastin

8 5

Glucophage

EMD Serono

Approved

—6

Inlyta

PPrism Pharmaceuticals

Approved

—7

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

3 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 9

Eloxatin

Teva

Phase 2

3 10

Tecentriq

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 3Recruiting

Colorectal Carcinoma

NCT07686640

Clinical

Trials by Indication[1]

Colorectal Carcinoma1 trial

Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer (SCRIT): A Multicenter Phase III Randomized Controlled Trial

Recruiting·SShandong Cancer Hospital and Institute·Phase 3·NCT07686640·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Consolidation treatment (With ICIs). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Consolidation treatment (With ICIs). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shandong Cancer Hospital and Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: SShandong Cancer Hospital and Institute

Consolidation treatment (With ICIs)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Colorectal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News